{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:45:04Z","timestamp":1790876704737,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07735-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:59:10Z","timestamp":1751378350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Affective and chronic fatigue symptoms are associated with serum neuronal damage markers in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Hussein Kadhem","family":"Al-Hakeim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder Naji","family":"Khudhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed-Omid","family":"Ranaei-Siadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fataneh","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Mirzajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7735_CR1","doi-asserted-by":"publisher","first-page":"e2577","DOI":"10.1002\/brb3.2577","volume":"12","author":"O Uwishema","year":"2022","unstructured":"Uwishema, O. et al. The Understanding of parkinson\u2019s disease through genetics and new therapies. Brain Behav. 12, e2577. https:\/\/doi.org\/10.1002\/brb3.2577 (2022).","journal-title":"Brain Behav."},{"key":"7735_CR2","unstructured":"Saini, N. et al. Motor and non-motor symptoms, drugs, and their mode of action in parkinson\u2019s disease (PD): a review. Med.  Chem. Res., 1\u201320 (2024)."},{"key":"7735_CR3","doi-asserted-by":"publisher","first-page":"101834","DOI":"10.1016\/j.arr.2022.101834","volume":"84","author":"ABRL Silva","year":"2023","unstructured":"Silva, A. B. R. L. et al. Premotor, nonmotor and motor symptoms of parkinson\u2019s disease: a new clinical state of the Art. Ageing Res. Rev. 84, 101834 (2023).","journal-title":"Ageing Res. Rev."},{"key":"7735_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch, E. C. & Hunot, S. Neuroinflammation in parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol. 8, 382\u2013397 (2009).","journal-title":"Lancet Neurol."},{"key":"7735_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fnins.2018.00626","volume":"12","author":"LM Butkovich","year":"2018","unstructured":"Butkovich, L. M., Houser, M. C. & Tansey, M. G. \u03b1-synuclein and noradrenergic modulation of immune cells in parkinson\u2019s disease pathogenesis. Front. NeuroSci. 12, 626 (2018).","journal-title":"Front. NeuroSci."},{"key":"7735_CR6","doi-asserted-by":"publisher","first-page":"e27750","DOI":"10.7759\/cureus.27750","volume":"14","author":"R Chikatimalla","year":"2022","unstructured":"Chikatimalla, R. et al. Depression in parkinson\u2019s disease: A narrative review. Cureus 14, e27750. https:\/\/doi.org\/10.7759\/cureus.27750 (2022).","journal-title":"Cureus"},{"key":"7735_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak, H., R\u00fcb, U., Gai, W. P. & Del Tredici, K. Idiopathic parkinson\u2019s disease: possible routes by which vulnerable neuronal types May be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517\u2013536 (2003).","journal-title":"J. Neural Transm."},{"key":"7735_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0026-895X(25)09102-3","volume":"36","author":"H Manev","year":"1989","unstructured":"Manev, H., Favaron, M., Guidotti, A. & Costa, E. Delayed increase of Ca2\u2009+\u2009influx elicited by glutamate: role in neuronal death. Mol. Pharmacol. 36, 106\u2013112 (1989).","journal-title":"Mol. Pharmacol."},{"key":"7735_CR9","doi-asserted-by":"crossref","unstructured":"Wang, K. K., Zhang, Z. & Moghieb, A. In Neural Regeneration401\u2013410 (Elsevier, 2015).","DOI":"10.1016\/B978-0-12-801732-6.00026-4"},{"key":"7735_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2021.08.029","volume":"130","author":"ME Huibregtse","year":"2021","unstructured":"Huibregtse, M. E., Bazarian, J. J., Shultz, S. R. & Kawata, K. The biological significance and clinical utility of emerging blood biomarkers for traumatic brain injury. Neurosci. Biobehav. Rev.. 130, 433\u2013447 (2021).","journal-title":"Neurosci. Biobehavioral Reviews"},{"key":"7735_CR11","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.3390\/ijms25042372","volume":"25","author":"S Silvestro","year":"2024","unstructured":"Silvestro, S., Raffaele, I., Quartarone, A. & Mazzon, E. Innovative insights into traumatic brain injuries: biomarkers and new Pharmacological targets. Int. J. Mol. Sci. 25, 2372 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"7735_CR12","unstructured":"Palumbo, B., Sabalich, I. & Tranfaglia, C. & Lucilla Parnetti, M. J. F. n. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer\u2019s disease? 23, 93 (2008)."},{"key":"7735_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2014.01.055","volume":"565","author":"M Brenner","year":"2014","unstructured":"Brenner, M. Role of GFAP in CNS injuries. Neurosci. Lett. 565, 7\u201313 (2014).","journal-title":"Neurosci. Lett."},{"key":"7735_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. Jama 324, 772\u2013781 (2020).","journal-title":"Jama"},{"key":"7735_CR15","doi-asserted-by":"crossref","unstructured":"das Neves, S. P., Sousa, J. C., Sousa, N., Cerqueira, J. J. & Marques, F. J. G. Altered astrocytic function in experimental neuroinflammation and multiple sclerosis. 69, 1341\u20131368 (2021).","DOI":"10.1002\/glia.23940"},{"key":"7735_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parkreldis.2004.07.002","volume":"11","author":"DV Schaf","year":"2005","unstructured":"Schaf, D. V. et al. S100B and NSE serum levels in patients with parkinson\u2019s disease. Parkinsonism Relat. Disord. 11, 39\u201343 (2005).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7735_CR17","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","volume":"271","author":"A Pilotto","year":"2024","unstructured":"Pilotto, A. et al. Plasma nfl, GFAP, amyloid, and p-tau species as prognostic biomarkers in parkinson\u2019s disease. J. Neurol. 271, 7537\u20137546. https:\/\/doi.org\/10.1007\/s00415-024-12669-7 (2024).","journal-title":"J. Neurol."},{"key":"7735_CR18","unstructured":"Pe\u00f1a-Zelayeta, L. et al. In Preprints (Preprints, 2025)."},{"key":"7735_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-013-0409-5","volume":"13","author":"L Marsh","year":"2013","unstructured":"Marsh, L. Depression and parkinson\u2019s disease: current knowledge. Curr. Neurol. Neurosci. Rep. 13, 1\u20139 (2013).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"7735_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/mds.27461","volume":"33","author":"M Siciliano","year":"2018","unstructured":"Siciliano, M. et al. Fatigue in parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 33, 1712\u20131723 (2018).","journal-title":"Mov. Disord."},{"key":"7735_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","volume":"19","author":"B M\u00fcller","year":"2013","unstructured":"M\u00fcller, B., Assmus, J., Herlofson, K., Larsen, J. P. & Tysnes, O. B. Importance of motor vs. non-motor symptoms for health-related quality of life in early parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 1027\u20131032 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7735_CR22","doi-asserted-by":"crossref","unstructured":"Lindqvist, D. et al. Non-motor symptoms in patients with parkinson\u2019s disease\u2013correlations with inflammatory cytokines in serum. (2012).","DOI":"10.1371\/journal.pone.0047387"},{"key":"7735_CR23","doi-asserted-by":"crossref","unstructured":"Sun, C. et al. Peripheral humoral immune response is associated with the Non-motor symptoms of parkinson\u2019s disease. Front.  Neurosci. Volume 13\u20132019 (2019).","DOI":"10.3389\/fnins.2019.01057"},{"key":"7735_CR24","first-page":"284","volume":"30","author":"FN Twisk","year":"2009","unstructured":"Twisk, F. N. & Maes, M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)\/chronic fatigue syndrome (CFS): CBT\/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME\/CFS. Neuroendocrinol. Lett. 30, 284\u2013299 (2009).","journal-title":"Neuroendocrinol. Lett."},{"key":"7735_CR25","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.1007\/s12035-018-1016-x","volume":"55","author":"M Maes","year":"2018","unstructured":"Maes, M. & Carvalho, A. F. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. Mol. Neurobiol. 55, 8885\u20138903 (2018).","journal-title":"Mol. Neurobiol."},{"key":"7735_CR26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin, X. Y., Zhang, S. P., Cao, C., Loh, Y. P. & Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 73, 1316\u20131324 (2016).","journal-title":"JAMA Neurol."},{"key":"7735_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of parkinson\u2019s disease. Lancet 403, 293\u2013304 (2024).","journal-title":"Lancet"},{"key":"7735_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/gps.2496","volume":"26","author":"M Andersson","year":"2011","unstructured":"Andersson, M., Zetterberg, H., Minthon, L., Blennow, K. & Londos, E. The cognitive profile and CSF biomarkers in dementia with lewy bodies and parkinson\u2019s disease dementia. Int. J. Geriatr. Psychiatry. 26, 100\u2013105 (2011).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"7735_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.nbd.2017.07.014","volume":"106","author":"R Rydbirk","year":"2017","unstructured":"Rydbirk, R. et al. Cytokine profiling in the prefrontal cortex of parkinson\u2019s disease and multiple system atrophy patients. Neurobiol. Dis. 106, 269\u2013278. https:\/\/doi.org\/10.1016\/j.nbd.2017.07.014 (2017).","journal-title":"Neurobiol. Dis."},{"key":"7735_CR30","doi-asserted-by":"publisher","first-page":"061","DOI":"10.29328\/journal.jnnd.1001052","volume":"5","author":"R Dutta","year":"2021","unstructured":"Dutta, R. Role of neuron specific enolase as a biomarker in parkinson\u2019s disease. J. Neurosci. Neurol. Disorders. 5, 061\u2013068 (2021).","journal-title":"J. Neurosci. Neurol. Disorders"},{"key":"7735_CR31","doi-asserted-by":"crossref","unstructured":"Gonzales, M. M. et al. Association of midlife depressive symptoms with regional Amyloid-\u03b2 and Tau in the Framingham heart study. J.  Alzheimer\u2019s Dis., 1\u201312 (2021).","DOI":"10.3233\/JAD-210232"},{"key":"7735_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/jcm12020511","volume":"12","author":"HK Al-Hakeim","year":"2023","unstructured":"Al-Hakeim, H. K., Al-Rubaye, H. T., Almulla, A. F., Al-Hadrawi, D. S. & Maes, M. Chronic fatigue, depression and anxiety symptoms in long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection. J. Clin. Med. 12, 511 (2023).","journal-title":"J. Clin. Med."},{"key":"7735_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12916-023-03120-1","volume":"21","author":"J Lin","year":"2023","unstructured":"Lin, J. et al. Plasma glial fibrillary acidic protein as a biomarker of disease progression in parkinson\u2019s disease: a prospective cohort study. BMC Med. 21, 420 (2023).","journal-title":"BMC Med."},{"key":"7735_CR34","doi-asserted-by":"crossref","unstructured":"Ridhaa, M. A. S., Al-Hakeim, H. K., Kahlol, M. K., Al-Naqeeb, T. H. & Maes, M. In children with transfusion-dependent thalassemia, inflammation and neuronal damage biomarkers are associated with affective and chronic fatigue symptoms. MedRxiv, 2023\u2009\u2013\u20092011 (2023).","DOI":"10.1101\/2023.11.21.23298798"},{"key":"7735_CR35","doi-asserted-by":"publisher","first-page":"e02082","DOI":"10.1002\/brb3.2082","volume":"11","author":"W Liu","year":"2021","unstructured":"Liu, W. & Tang, J. Association between diabetes mellitus and risk of parkinson\u2019s disease: a prisma-compliant meta\u2010analysis. Brain Behav. 11, e02082 (2021).","journal-title":"Brain Behav."},{"key":"7735_CR36","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan, H. et al. Type 2 diabetes as a determinant of parkinson\u2019s disease risk and progression. Mov. Disord. 36, 1420\u20131429 (2021).","journal-title":"Mov. Disord."},{"key":"7735_CR37","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/nu15163585","volume":"15","author":"VA Ruiz-Pozo","year":"2023","unstructured":"Ruiz-Pozo, V. A. et al. The molecular mechanisms of the relationship between insulin resistance and parkinson\u2019s disease pathogenesis. Nutrients 15, 3585 (2023).","journal-title":"Nutrients"},{"key":"7735_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jad.2021.07.057","volume":"294","author":"NR Morelli","year":"2021","unstructured":"Morelli, N. R. et al. Increased nitro-oxidative toxicity in association with metabolic syndrome, atherogenicity and insulin resistance in patients with affective disorders. J. Affect. Disord. 294, 410\u2013419 (2021).","journal-title":"J. Affect. Disord."},{"key":"7735_CR39","doi-asserted-by":"publisher","first-page":"1194769","DOI":"10.3389\/fnmol.2023.1194769","volume":"16","author":"HK Al-Hakeim","year":"2023","unstructured":"Al-Hakeim, H. K., Khairi Abed, A., Rouf Moustafa, S., Almulla, A. F. & Maes, M. Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID. Front. Mol. Neurosci. 16, 1194769 (2023).","journal-title":"Front. Mol. Neurosci."},{"key":"7735_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1017\/neu.2024.10","volume":"36","author":"A Vojdani","year":"2024","unstructured":"Vojdani, A., Almulla, A. F., Zhou, B., Al-Hakeim, H. K. & Maes, M. Reactivation of herpesvirus type 6 and IgA\/IgM-mediated responses to activin-A underpin long COVID, including affective symptoms and chronic fatigue syndrome. Acta Neuropsychiatrica. 36, 172\u2013184 (2024).","journal-title":"Acta Neuropsychiatrica"},{"key":"7735_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"7735_CR42","doi-asserted-by":"crossref","unstructured":"Perlmutter, J. S. Assessment of Parkinson disease manifestations. Current Protocols Neurosci. Chap 10. Unit10.11 (2009).","DOI":"10.1002\/0471142301.ns1001s49"},{"key":"7735_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS\u2010UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"7735_CR44","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS\u2010UPDRS): scale presentation and clinimetric testing results. Mov. Disorders: Official J. Mov. Disorder Soc. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"key":"7735_CR45","first-page":"109","volume":"14","author":"M Herrmann","year":"1999","unstructured":"Herrmann, M. et al. Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor. Neurol. Neurosci. 14, 109\u2013114 (1999).","journal-title":"Restor. Neurol. Neurosci."},{"key":"7735_CR46","doi-asserted-by":"crossref","unstructured":"Isgr\u00f2, M. A., Bottoni, P. & Scatena, R. J. A. I. C. B. F. B. T. C. F. A. C. R. Neuron-specific enolase A. A.B.omarker: B.ochemical A.d C.inical A.pects. Advances Cancer Biomarkers, 125\u2013143 (2015).","DOI":"10.1007\/978-94-017-7215-0_9"},{"key":"7735_CR47","doi-asserted-by":"crossref","unstructured":"Constantinescu, R., Zetterberg, H., Holmberg, B. & Rosengren, L. J. P. & disorders, r. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. 15, 205\u2013212 (2009).","DOI":"10.1016\/j.parkreldis.2008.05.001"},{"key":"7735_CR48","doi-asserted-by":"publisher","unstructured":"Chaves, M. L. et al. Serum levels of S100B and NSE proteins in Alzheimer\u2019s disease patients. J. Neuroinflamm. 7 https:\/\/doi.org\/10.1186\/1742-2094-7-6 (2010).","DOI":"10.1186\/1742-2094-7-6"},{"key":"7735_CR49","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnagi.2020.00156","volume":"12","author":"E Papu\u0107","year":"2020","unstructured":"Papu\u0107, E. & Rejdak, K. Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in parkinson\u2019s disease. Front. Aging Neurosci. 12, 156 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"7735_CR50","doi-asserted-by":"crossref","unstructured":"Christl, J. et al. Association of cerebrospinal fluid S100B protein with core biomarkers and cognitive deficits in prodromal and mild alzheimer\u2019s disease. 72, 1119\u20131127 (2019).","DOI":"10.3233\/JAD-190550"},{"key":"7735_CR51","doi-asserted-by":"crossref","unstructured":"Streitb\u00fcrger, D. P. et al. Validating serum S100B and neuron-specific enolase as biomarkers for the human brain\u2013a combined serum, gene expression and MRI study. (2012).","DOI":"10.1371\/journal.pone.0043284"},{"key":"7735_CR52","doi-asserted-by":"publisher","unstructured":"Kim, H. J., Tsao, J. W. & Stanfill, A. G. The current state of biomarkers of mild traumatic brain injury. JCI Insight. 3 https:\/\/doi.org\/10.1172\/jci.insight.97105 (2018).","DOI":"10.1172\/jci.insight.97105"},{"key":"7735_CR53","doi-asserted-by":"publisher","first-page":"e0234082","DOI":"10.1371\/journal.pone.0234082","volume":"15","author":"MZ Le\u00f3n-Lozano","year":"2020","unstructured":"Le\u00f3n-Lozano, M. Z. et al. Cerebrospinal fluid levels of neuron-specific enolase predict the severity of brain damage in newborns with neonatal hypoxic-ischemic encephalopathy treated with hypothermia. PloS One. 15, e0234082 (2020).","journal-title":"PloS One"},{"key":"7735_CR54","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/brain\/aws250","volume":"135","author":"K Sathe","year":"2012","unstructured":"Sathe, K. et al. S100B is increased in parkinson\u2019s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-\u03b1 pathway. Brain 135, 3336\u20133347 (2012).","journal-title":"Brain"},{"key":"7735_CR55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1468-1331.2006.01667.x","volume":"14","author":"KR Wilhelm","year":"2007","unstructured":"Wilhelm, K. R. et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood Sera of parkinson\u2019s disease patients. Eur. J. Neurol. 14, 327\u2013334 (2007).","journal-title":"Eur. J. Neurol."},{"key":"7735_CR56","doi-asserted-by":"crossref","unstructured":"Carvalho, D. et al. Overnight S100B in parkinson\u2019s disease: A glimpse into sleep-related neuroinflammation. 608, 57\u201363 (2015).","DOI":"10.1016\/j.neulet.2015.10.010"},{"key":"7735_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-018-0547-3","volume":"19","author":"C Fardell","year":"2018","unstructured":"Fardell, C. et al. S100B polymorphisms are associated with age of onset of parkinson\u2019s disease. BMC Med. Genet. 19, 1\u20139 (2018).","journal-title":"BMC Med. Genet."},{"key":"7735_CR58","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/brainsci13091334","volume":"13","author":"T Kozlowski","year":"2023","unstructured":"Kozlowski, T., Bargiel, W., Grabarczyk, M. & Skibinska, M. Peripheral S100B protein levels in five major psychiatric disorders: a systematic review. Brain Sci. 13, 1334 (2023).","journal-title":"Brain Sci."},{"key":"7735_CR59","doi-asserted-by":"crossref","unstructured":"Zhang, W. et al. The blood brain barrier in cerebral ischemic injury\u2013Disruption and repair. 1, 34\u201353 (2020).","DOI":"10.1016\/j.hest.2019.12.004"},{"key":"7735_CR60","doi-asserted-by":"crossref","unstructured":"Yu, Y. et al. Perfluorooctane sulfonate disrupts the blood brain barrier through the crosstalk between endothelial cells and astrocytes in mice. 256, 113429 (2020).","DOI":"10.1016\/j.envpol.2019.113429"},{"key":"7735_CR61","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1046\/j.1471-4159.1997.69062294.x","volume":"69","author":"J Hu","year":"1997","unstructured":"Hu, J., Ferreira, A. & Van Eldik, L. J. S100\u03b2 induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem. 69, 2294\u20132301 (1997).","journal-title":"J. Neurochem."},{"key":"7735_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/18756190MTA44NjEs3","volume":"19","author":"U Langeh","year":"2021","unstructured":"Langeh, U. & Singh, S. Targeting S100B protein as a surrogate biomarker and its role in various neurological disorders. Curr. Neuropharmacol. 19, 265\u2013277 (2021).","journal-title":"Curr. Neuropharmacol."},{"key":"7735_CR63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1189\/jlb.0306198","volume":"81","author":"R Bianchi","year":"2007","unstructured":"Bianchi, R., Adami, C., Giambanco, I. & Donato, R. S100B binding to RAGE in microglia stimulates COX-2 expression. J. Leucocyte Biology. 81, 108\u2013118 (2007).","journal-title":"J. Leucocyte Biology"},{"key":"7735_CR64","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1089\/neu.2019.6475","volume":"37","author":"J Baecker","year":"2020","unstructured":"Baecker, J. et al. Treatment with the neurotrophic protein S100B increases synaptogenesis after traumatic brain injury. J. Neurotrauma. 37, 1097\u20131107 (2020).","journal-title":"J. Neurotrauma"},{"key":"7735_CR65","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1073\/pnas.052020999","volume":"99","author":"H Nishiyama","year":"2002","unstructured":"Nishiyama, H., Knopfel, T., Endo, S. & Itohara, S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc. Natl. Acad. Sci. U S A. 99, 4037\u20134042. https:\/\/doi.org\/10.1073\/pnas.052020999 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"7735_CR66","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00701-013-1720-2","volume":"155","author":"A Kleindienst","year":"2013","unstructured":"Kleindienst, A., Grunbeck, F., Buslei, R., Emtmann, I. & Buchfelder, M. Intraperitoneal treatment with S100B enhances hippocampal neurogenesis in juvenile mice and after experimental brain injury. Acta Neurochir. (Wien). 155, 1351\u20131360. https:\/\/doi.org\/10.1007\/s00701-013-1720-2 (2013).","journal-title":"Acta Neurochir. (Wien)"},{"key":"7735_CR67","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine, T. J. et al. CSF A\u03b242 and Tau in parkinson\u2019s disease with cognitive impairment. Mov. Disord. 25, 2682\u20132685 (2010).","journal-title":"Mov. Disord."},{"key":"7735_CR68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo, T., Noble, W. & Hanger, D. P. J. A. N. Roles of Tau protein in health and disease. Acta Neuropathol. 133, 665\u2013704 (2017).","journal-title":"Acta Neuropathol."},{"key":"7735_CR69","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/0115672050271523231111192725","volume":"20","author":"ZD Green","year":"2023","unstructured":"Green, Z. D., Kueck, P. J., John, C. S., Burns, J. M. & Morris, J. K. Blood biomarkers discriminate cerebral amyloid status and cognitive diagnosis when collected with ACD-A anticoagulant. Curr. Alzheimer Res. 20, 557 (2023).","journal-title":"Curr. Alzheimer Res."},{"key":"7735_CR70","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jad.2023.03.072","volume":"331","author":"HK Al-Hakeim","year":"2023","unstructured":"Al-Hakeim, H. K., Al-Naqeeb, T. H., Almulla, A. F. & Maes, M. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and Lowered calcium. J. Affect. Disord. 331, 300\u2013312 (2023).","journal-title":"J. Affect. Disord."},{"key":"7735_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jpsychires.2021.09.012","volume":"144","author":"P Steinacker","year":"2021","unstructured":"Steinacker, P. et al. Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. J. Psychiatr. Res. 144, 54\u201358 (2021).","journal-title":"J. Psychiatr. Res."},{"key":"7735_CR72","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","volume":"33","author":"S Lotankar","year":"2017","unstructured":"Lotankar, S., Prabhavalkar, K. S. & Bhatt, L. K. Biomarkers for parkinson\u2019s disease: recent advancement. Neurosci. Bull. 33, 585\u2013597 (2017).","journal-title":"Neurosci. Bull."},{"key":"7735_CR73","doi-asserted-by":"crossref","unstructured":"Luger, S. et al. Glial fibrillary acidic protein serum levels distinguish between intracerebral hemorrhage and cerebral ischemia in the early phase of stroke. 63, 377\u2013385 (2017).","DOI":"10.1373\/clinchem.2016.263335"},{"key":"7735_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41531-023-00457-5","volume":"9","author":"L Mu\u00f1oz-Delgado","year":"2023","unstructured":"Mu\u00f1oz-Delgado, L. et al. Peripheral inflammatory immune response differs among sporadic and Familial parkinson\u2019s disease. Npj Parkinson\u2019s Disease. 9, 12 (2023).","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"7735_CR75","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jad.2023.11.078","volume":"347","author":"HK Al-Hakeim","year":"2024","unstructured":"Al-Hakeim, H. K., Twaij, B. A. A. R., Al-Naqeeb, T. H., Moustafa, S. R. & Maes, M. Neuronal damage and inflammatory biomarkers are associated with the affective and chronic fatigue-like symptoms due to end-stage renal disease. J. Affect. Disord. 347, 220\u2013229 (2024).","journal-title":"J. Affect. Disord."},{"key":"7735_CR76","doi-asserted-by":"crossref","unstructured":"Almulla, A. F., Maes, M., Zhou, B., Al-Hakeim, H. K. & Vojdani, A. Brain-targeted autoimmunity is strongly associated with long COVID and its chronic fatigue syndrome as well as its affective symptoms. Journal Adv. Research (2024).","DOI":"10.21203\/rs.3.rs-4301181\/v1"},{"key":"7735_CR77","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell, J., Blunt, E. & Edison, P. Incretin and insulin signaling as novel therapeutic targets for alzheimer\u2019s and parkinson\u2019s disease. Mol. Psychiatry. 28, 217\u2013229. https:\/\/doi.org\/10.1038\/s41380-022-01792-4 (2023).","journal-title":"Mol. Psychiatry"},{"key":"7735_CR78","doi-asserted-by":"publisher","first-page":"e12760","DOI":"10.1111\/nan.12760","volume":"48","author":"F Bassil","year":"2022","unstructured":"Bassil, F. et al. Impaired brain insulin signalling in parkinson\u2019s disease. Neuropathol. Appl. Neurobiol. 48, e12760 (2022).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"7735_CR79","doi-asserted-by":"crossref","unstructured":"Gruber, J. et al. Impact of insulin and insulin resistance on brain dopamine signalling and reward processing\u2013an underexplored mechanism in the pathophysiology of depression? Neuroscience & Biobehavioral Reviews, 105179 (2023).","DOI":"10.1016\/j.neubiorev.2023.105179"},{"key":"7735_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12640-013-9439-7","volume":"25","author":"J Renaud","year":"2014","unstructured":"Renaud, J., Bournival, J., Zottig, X. & Martinoli, M. G. Resveratrol protects daergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization. Neurotox. Res. 25, 110\u2013123 (2014).","journal-title":"Neurotox. Res."},{"key":"7735_CR81","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12264-019-00459-5","volume":"36","author":"CJ Su","year":"2020","unstructured":"Su, C. J. et al. Thioredoxin-interacting protein (TXNIP) regulates Parkin\/PINK1-mediated mitophagy in dopaminergic neurons under high-glucose conditions: implications for molecular links between parkinson\u2019s disease and diabetes. Neurosci. Bull. 36, 346\u2013358 (2020).","journal-title":"Neurosci. Bull."},{"key":"7735_CR82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jpm12010023","volume":"12","author":"HK Al-Hakeim","year":"2022","unstructured":"Al-Hakeim, H. K., Hadi, H. H., Jawad, G. A. & Maes, M. Intersections between copper, \u03b2-arrestin-1, calcium, FBXW7, CD17, insulin resistance and atherogenicity mediate depression and anxiety due to type 2 diabetes mellitus: a nomothetic network approach. J. Personalized Med. 12, 23 (2022).","journal-title":"J. Personalized Med."},{"key":"7735_CR83","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1017\/S1092852921000432","volume":"27","author":"RF Mousa","year":"2022","unstructured":"Mousa, R. F., Smesam, H. N., Qazmooz, H. A., Al-Hakeim, H. K. & Maes, M. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr. 27, 676\u2013690 (2022).","journal-title":"CNS Spectr."},{"key":"7735_CR84","doi-asserted-by":"publisher","first-page":"106844","DOI":"10.1016\/j.clineuro.2021.106844","volume":"208","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Possible inflammatory mechanisms and predictors of parkinson\u2019s disease patients with fatigue (brief review). Clin. Neurol. Neurosurg. 208, 106844 (2021).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"7735_CR85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/ane.12977","volume":"138","author":"K Herlofson","year":"2018","unstructured":"Herlofson, K. et al. Inflammation and fatigue in early, untreated parkinson\u2019s disease. Acta Neurol. Scand. 138, 394\u2013399 (2018).","journal-title":"Acta Neurol. Scand."},{"key":"7735_CR86","first-page":"437","volume":"3","author":"G \u00d6zer","year":"2019","unstructured":"\u00d6zer, G., Ad\u0131g\u00fczel, H., K\u0131rmac\u0131, Z. \u0130. K. & Ergun, N. Is insulin resistance associated with fatigue, the severity of the disease and motor disability in idiopathic parkinson\u2019s disease? J. Surg. Med. 3, 437\u2013440 (2019).","journal-title":"J. Surg. Med."},{"key":"7735_CR87","doi-asserted-by":"publisher","first-page":"102406","DOI":"10.1016\/j.nicl.2020.102406","volume":"28","author":"M De Dreu","year":"2020","unstructured":"De Dreu, M., Schouwenaars, I., Rutten, G., Ramsey, N. & Jansma, J. Fatigue in brain tumor patients, towards a neuronal biomarker. NeuroImage: Clin. 28, 102406 (2020).","journal-title":"NeuroImage: Clin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07735-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:48:29Z","timestamp":1751381309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07735-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7735"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07735-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been approved by the institutional ethics committee of the University of Kufa (2109\/2023). The study adhered to both Iraqi and international ethical and privacy laws, including the International Conference on Harmonization of Good Clinical Practice, the Belmont Report, the CIOMS Guidelines, and the World Medical Association\u2019s Declaration of Helsinki. Before participating in this study, each subject provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20647"}}